On the patents behind CRISPR babies

Just as everyone, we heard the news on the first genetically engineered babies in mankind’s history. We took a closer look this morning into our patent data to check if there’s any published details already available. Indeed, the Chinese patent office publishes its data earlier than the other countries, sometimes as early as 3 months after the filing, so if the babies are born now, there’s a good chance that the Chinese patent data is already available.

Continue reading

Myths and realities on DuPont CRISPR assets

On the agriculture side, IAM just published this week some basic quantitative data analytics spotting DuPont as the leader in CRISPR patent assets. The IAM interview also highlighted some questions about the licensing position of DuPont in the CRISPR patent battle. This was quite surprising to read for us as this information has been publicly known since 2014 and regularly compiled in both our patent and licensing landscapes. Let’s take a closer scrutiny into the DuPont CRISPR assets. In our monitoring of licensing data since 2014, we have actually spotted DuPont Pioneer as one of the earliest player to position their licensing-in in a very strategic way:

Continue reading

May 2017 – CRISPR update

The CRISPR patent landscape keeps on steadily growing, with an additional 70 patent publications last month. We have now monitored more than 1400 patent families in our latest CRISPR patent analytics data set. In the past few weeks, our patent landscape data was quoted in the WIPO magazine coverage of CRISPR, while our expert Fabien Palazzoli had the opportunity to present his latest findings at the Cell Line Development and Engineering conference in Amsterdam and to Deftech in Switzerland.

Continue reading

Recent developments in the CRISPR patent landscape

The CRISPR patent landscape keeps on developing with now an average of two new patent publications every day. We have now searched, reviewed and categorized 1198 patent families in our February 2016 CRISPR patent analytics data set. The recent conclusions by the USPTO on the CRISPR pioneering patent interference has received significant media attention and finally confirmed the diversity of the CRISPR licensing landscape. We have provided our 2017 key findings to a number of analysts in the field, and are working hard to keep on extracting and sorting meaningful CRISPR patent coverage information for our customers on a monthly basis.

Continue reading

Will the CRISPR patent landscape soon move to a one-stop license shopping?

The past 24 hours have brought new light and significant moves in the complex CRISPR patent landscape.

First (that was in European time zone!), our CRISPR expert Fabien Palazzoli celebrated the 1000th CRISPR patent family extraction out of the worldwide published patent databases. Our next monthly update will actually feature more than 1050 classified and categorized CRISPR patent families – more than 10 times the initial set of our first landscape release back in summer 2014!

Continue reading

More CRISPR interfering inventors may come from Vilnius

Earlier this month, we were interviewed by The Scientist regarding the side inventorship dispute between Feng Zhang and Luciano Marraffini on some of the Broad patent applications. Public registers at the USPTO, WIPO and the EPO expose further details of the otherwise un-publicized legal battles for invention ownership between their employers (the Broad Institute of Harvard and MIT and Rockfeller University), back from the 2012-2013 early filings.

Continue reading

Zoom on CAR-T in the CRISPR landscape

The CRISPR technology has a wide range of target applications, from agronomy to medicine. As we celebrate the 2nd birthday of CRISPR patent analytics services at IPStudies and the 4th year of the CRISPR-Cas9 invention, a few application areas show an increasing competitive activity in the landscape. On CAR-T (chimeric antigen receptor T) cell immunotherapy, we now find more than twenty patent applications in the CRISPR landscape. As could be expected from their marketing/communication, a number of pharmaceutical players and CRISPR technology development pioneers have actively positioned their IP in that domain, namely:

Continue reading